San Francisco, CA January 9, 2012. Medizone International, Inc. (MZEI:OB) MZEI:QB), the research and development company behind
AsepticSure disinfection technology, announced today that filings of its recently granted lead patent application (Canadian Patent No 2735739) have been completed in the United States, Mexico, Brazil, China and Japan.
AsepticSure’s proven efficacy against a vast spectrum of pathogenic bacteria, fungi, spores and viruses now paves the way for its use in large-scale reductions of hospital acquired infections (HAIs) in medical centers, health care organizations and hospitals around the world.
It is also the only disinfection technology in existence that has reliably and repeatedly demonstrated in peer-reviewed research, a 100% kill-rate with deadly pathogens such as C-difficile and MRSA, the root source of superbug infections, globally.
Medizone’s lead patent was granted on November 22, 2011 by the Canadian Intellectual Property Office (patent office) for processes and systems relating to the platform technology.
Medizone Board Chairman and CEO, Edwin Marshall, added, “Shareholders should be highly encouraged by the continued success of our intellectual property protection program. Additional filings are currently in process for all of the European Union, Great Britain, India, Korea, Australia and South Africa. These filings will be submitted over the next few weeks."